Overall, our data shows that a KIT and MEK inhibitor combination has distinct advantages over treatments with KIT inhibitors alone in killing GIST cells and triple combination with addition of a PI3K inhibitor is even better. Here, MAP2K7 is linked to gastrointestinal stromal tumor.